Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 142Gastrointestinal Stromal Tumors 71Leukemia 69Leukemia, Myeloid, Chronic-Phase 50Precursor Cell Lymphoblastic Leukemia-Lymphoma 43Blast Crisis 22Neoplasms 15Brain Neoplasms 15Philadelphia Chromosome 14Melanoma 13Sarcoma 12Neoplasm Metastasis 12Leukemia, Myeloid, Acute 12Leukemia, Myeloid, Accelerated Phase 12Glioblastoma 12Lung Neoplasms 11Prostatic Neoplasms 10Leukemia, Myeloid 9Gliosarcoma 9Glioma 8Breast Neoplasms 8Primary Myelofibrosis 7Leukemia, Myelomonocytic, Chronic 7Central Nervous System Neoplasms 7Astrocytoma 7Recurrence 6Polycythemia Vera 6Ovarian Neoplasms 6Oligodendroglioma 6Myeloproliferative Disorders 6

Interventions

Irinotecan 6Gemcitabine 5130-nm albumin-bound paclitaxel 5Oxaliplatin 4Fluorouracil 4Capecitabine 4Bevacizumab 4Albumin-Bound Paclitaxel 4napabucasin 3Ocoxin 3Leucovorin 3pembrolizumab 2Sorafenib 2Paclitaxel 2Nivolumab 2Drug Therapy 2Cyclophosphamide 2Colonoscopy 2Cetuximab 2Bupivacaine 2Aspirin 2Ascorbic Acid 2trifluridine tipiracil drug combination 1trametinib 1pralsetinib 1penpulimab 1ozanimod 1lutetium Lu 177 dotatate 1linifanib 1hetrombopag 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Digestive System Diseases × Imatinib Mesylate × Clear all
NCT00867113 2018-03-14

Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)

Novartis

Phase 2 Completed
91 enrolled 11 charts
GastrointestinalSarcoma

Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡